Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS-4718 + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Verastem Oncology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of three agents: VS-4718, nab-paclitaxel, and gemcitabine. VS-4718 is an orally bioavailable small molecule inhibitor of focal adhesion kinase (FAK), which blocks FAK autophosphorylation at Tyr397 and disrupts integrin-mediated signaling pathways such as ERK, JNK/MAPK, and PI3K/Akt. This inhibition reduces cancer stem cell populations and impairs tumor cell migration, proliferation, and survival[1][3][4]. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor that interferes with mitosis in rapidly dividing cells; it is marketed under the brand name Abraxane[7]. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA strands during replication; it is marketed as Gemzar[7]. The combination of these drugs has been investigated for synergistic antitumor effects in various cancers including pancreatic cancer.
- Brand names
- Abraxane (nab-paclitaxel)Gemzar (gemcitabine)
- Other names
- nab-paclitaxelgemcitabine
02
Targets
POLA1 (DNA polymerase alpha)FAK (Focal adhesion kinase)PTK2BRRM1TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on VS-4718 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS-4718 + nab-paclitaxel + gemcitabine.